Inici › Limfoma de Burkitt › Maryland › Baltimore
Assaigs clínics de Limfoma de Burkitt a Baltimore, MD
8 estudis de Limfoma de Burkitt busquen participants en centres de Baltimore i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
ReclutantFase 2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
ReclutantFase 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
ReclutantFase 2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ReclutantFase 3
- Johns Hopkins Asthma & Allergy Center, Baltimore
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
ReclutantFase 1
- University of Maryland, Baltimore
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
ReclutantFase 2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
ReclutantFase 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
ReclutantFase 1
- University of Maryland, Baltimore
Assaigs de Limfoma de Burkitt en altres ciutats
- Houston, TX21 estudis
- Milwaukee, WI16 estudis
- Philadelphia, PA16 estudis
- New York City, NY14 estudis
- Chicago, IL14 estudis
- Cincinnati, OH12 estudis
- Atlanta, GA12 estudis
- Seattle, WA11 estudis
- Boston, MA10 estudis
- Durham, NC10 estudis
- Aurora, CO10 estudis
- Los Angeles, CA10 estudis
Altres estudis a Baltimore
- Càncer de pulmó de cèl·lules no petites60 estudis
- Càncer de mama47 estudis
- Càncer de pròstata43 estudis
- Càncer de pulmó40 estudis
- Càncer (tots els tipus)37 estudis
- Càncer colorrectal31 estudis
- Càncer de pàncrees31 estudis
- Càncer metastàtic28 estudis
- Obesitat25 estudis
- Insuficiència cardíaca24 estudis
- Càncer de bufeta24 estudis
- Ictus22 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.